^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

Published date:
02/24/2021
Excerpt:
...gilteritinib also displayed potency against ROS1 fusion gene-expressing lung cancer cell lines (HCC78 cells harbor SLC34A2-ROS1 and JFCR-168 harbor CD74-ROS1…)
DOI:
10.1038/s41467-021-21396-w